These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7882330)

  • 1. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
    Anderson PM; Meyers DE; Hasz DE; Covalcuic K; Saltzman D; Khanna C; Uckun FM
    Cancer Res; 1995 Mar; 55(6):1321-7. PubMed ID: 7882330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
    Ek O; Waurzyniak B; Myers DE; Uckun FM
    Clin Cancer Res; 1998 Jul; 4(7):1641-7. PubMed ID: 9676838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
    Ramakrishnan S; Uckun FM; Houston LL
    J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
    Piselli P; Vendetti S; Poccia F; Cicconi R; Mattei M; Bolognesi A; Stirpe F; Colizzi V
    J Biol Regul Homeost Agents; 1995; 9(2):55-62. PubMed ID: 9127634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood.
    Ramakrishnan S; Houston LL
    Cancer Res; 1985 May; 45(5):2031-6. PubMed ID: 3986759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
    Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
    J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins to a human melanoma-associated antigen: resistance to pokeweed antiviral protein conjugates in vitro.
    Morgan AC; Bordonaro J; Pearson JW; Sivam G
    J Natl Cancer Inst; 1987 Jun; 78(6):1101-6. PubMed ID: 3473251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
    Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM
    Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.